Selinexor (KPT-330) in Older Patients With Relapsed AML
Public ClinicalTrials.gov record NCT02088541. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except for AML M3, after one prior therapy only, who have never undergone and who are not currently eligible for stem cell transplantation and are currently deemed unfit for intensive chemotherapy.
Study identification
- NCT ID
- NCT02088541
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 317 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2014 (Type not available)
- Primary completion
- Jan 8, 2018 (Actual)
- Completion
- Jan 8, 2018 (Actual)
- Last update posted
- Jan 26, 2023
2014 – 2018
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jonsson Comprehensive Cancer Center / University of California, Los Angeles | Los Angeles | California | 90024 | — |
| Sutter Oncology & Hematology | Sacramento | California | 95816 | — |
| Stanford Cancer Institute / Stanford University | Stanford | California | 94304 | — |
| Colorado Blood Cancer Institute/Sarah Cannon Research Institute | Denver | Colorado | 80218 | — |
| Yale Cancer Center / Yale University | New Haven | Connecticut | 06510 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Winship Cancer Institute / Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| University of Kansas Hospital | Kansas City | Kansas | 66160 | — |
| Sidney Kimmel Comprehensive Cancer Center / John Hopkins University | Baltimore | Maryland | 21287 | — |
| University of Massachusetts Medical School | Worcester | Massachusetts | 01655 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109-0944 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Westchester Medical Center / New York Medical College | Hawthorne | New York | 10532 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| New York Presbyterian Hospital / Weill Cornell Medical College | New York | New York | 10065 | — |
| Duke Cancer Care | Durham | North Carolina | 27705 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Milton S. Hershey Medical Center / Penn State | Hershey | Pennsylvania | 17033 | — |
| Tennessee Oncology/Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Vanderbilt-Ingram Cancer Center / Vanderbilt University | Nashville | Tennessee | 37215 | — |
| MD Anderson Cancer Center / University of Texas | Houston | Texas | 77030 | — |
| Texas Transplant Institute/Sarah Cannon Research Institute | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02088541, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2023 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02088541 live on ClinicalTrials.gov.